Champions Oncology Ltd.

championsoncology.com

Formerly Champions Biotechnology, Champions Sports

High-Tech Company
Public Company

(OTCQB: CSBR), (NASDAQ CM: CSBR)

TECH VERTICALS

Analysis, Biologicals, Biotechnology, Identification, Life Sciences, MedTech, Oncology

General Data

Sector	Biomed
Company Stage:	Revenue Growth
Established	2007
Number of Employees	105
Reg. Number:	abCDe

DESCRIPTION

Champions Oncology specialises in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The company developed a CTG platform through the procurement, development and characterization of Tumorgrafts within multiple cancer types.

TECHNOLOGY

- Tumorgraft (CTG) Platform is a novel approach based upon the implantation of primary human tumors in immune-deficient mice followed by propagation of the resulting engraftments, or Tumorgrafts, in a manner that preserves the biological characteristics of the original human tumor.
- Personalized Oncology Solutions, or POS, to oncologists by establishing and administering expert tumor panels for their patients to analyze medical records and test results to assist in understanding conventional and experimental options and to identify and arrange for testing, analysis and study of the patients’ cancer tissues.
- Personalized Tumorgraft development, drug studies and genome sequencing as part of its POS, whereby physicians can evaluate the effects of cancer drugs on their patients’ Tumorgrafts and understand the genetic makeup of their patient’s tumor, enabling them to better select treatment regimens that may be efficacious to the patient.

ESTIMATED ANNUAL SALES

	TARGET MARKETS
	Pharmaceutical and biotechnology companies, Oncologists, Patients with cancer.

	BUSINESS MODEL
	B2C

COMPETITORS

CrownBio , Mitra Biotech , Madrigal Pharmaceuticals

REMARKS

Date

Remark

Champions Oncology was originally incorporated in 1985 as Champions Sports. It was listed on the OTC. In January of 2007 the company announced the change of its name to Champions Biotechnology, Inc. The Company sold its Champions service mark and concept for sports themed restaurants to Marriott International, Inc. in 1997 and sought a new business direction. The change of name in 2007 reflected the decision of the Company to focus on biotechnology as its new business approach. In April 2011 the company changed its name again to its current one.

CONTACT INFO

Expand / Collapse All

Main Address: Hackensack, United States

Address	One University Plaza, Suite 307
City	Hackensack
State/Province	NJ
Country	United States
Zip	07601

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: Jerusalem, Israel

Address	1 Agd. Sport Hapoel St.
City	Jerusalem
Country	Israel
Zip	9695101

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: Rockville, United States

Address	1330 Piccard Drive, Suite 025
City	Rockville
State/Province	MD
Country	United States
Zip	20850

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: London, United Kingdom

Address	2 Royal College St., London BioScience Innovation Centre
City	London
Country	United Kingdom
Zip	NW1 0NH

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title
Dr. Ronnie Morris	CEO & President
Mr. David Barry Miller	CFO
Mr. Michael Ritchie	CCO
Ms. Karin Abarca-Heidemann	EVP, Global Scientific Operations

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Chairman	Former CEO, Champions Oncology
abC Defghij	Board Member	General Partner, Co-Founder, Israel Biotech Fund
abC Defghij	Board Member	Chief Scientific & Innovation Officer, Champions Oncology
abC Defghij	Board Member	CEO & Founder, Avalere Health
abC Defghij	Board Member	CEO, Champions Oncology
abC Defghij	Board Member	General Partner, Battery Ventures

Mergers & Acquisitions

Round

Date

Stage

Amount

Valuation

Reverse Merger

Jan. 22, 2007

abCDe

Public Offerings

Deal Date	Type of Offering	Exchange	Amount Raise	Valuation	Remarks
Aug. 21, 2015	Listing	NASDAQ CM	abCDe	abCDe

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

PIPE

Mar. 13, 2015

Initial Revenues

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Private Equity Fund	abCDe
abC Defghij	Investment Company	abCDe
abC Defghij	Private Investor	abCDe

PIPE

Dec. 05, 2014

Initial Revenues

abCDe

A convertible loan.

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe

PIPE

Jan. 29, 2013

Initial Revenues

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe	Led the round
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Private Equity Fund	abCDe
abC Defghij	Hedge Fund	abCDe
abC Defghij	Investment Company	abCDe
abC Defghij	Investment Company	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Other	abCDe

PIPE

Apr. 05, 2011

Initial Revenues

abCDe

PIPE

Jan. 05, 2010

Initial Revenues

abCDe

PIPE

Apr. 23, 2008

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Private Equity Fund	abCDe
abC Defghij	Investment Company	abCDe

	Acquisitions made by Champions

Acquired Company	Sector	Date	Amount	Remarks
abC Defghij	Biomed...	May. 21, 2007	abCDe

Last Updated:	abCDe
IVC Number:	abCDe